SCHEMBL30362089

SCHEMBL30362089

OC(c1ccc(F)c(Br)c1)C(F)F

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 2/20 0.34
CES2 O00748 1/20 0.33
CES1 P23141 1/20 0.33
SYK P43405 1/20 0.33
VCP P55072 1/20 0.32
ADRB1 P08588 1/20 0.32
ADRA2A P08913 1/20 0.32
ADRB3 P13945 1/20 0.32
ADRA2B P18089 1/20 0.32
ADRA2C P18825 1/20 0.32
CYP1A2 P05177 1/20 0.31
CYP2D6 P10635 1/20 0.31
CYP2C9 P11712 1/20 0.31
CYP2C19 P33261 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
KDM4E B2RXH2 1/20 0.30
DPP4 P27487 1/20 0.30
IDO1 P14902 1/20 0.30
TDO2 P48775 1/20 0.30
AKT1 P31749 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31191131 1.00 PARP1 (0.34) PARP1CES2CES1SYKVCP
SCHEMBL23232366 0.81 CES2 (0.48) CES2CES1SYKADRB1ADRA2A
SCHEMBL3709776 0.81 PARP1 (0.36) PARP1CES2CES1VCPADRB1
SCHEMBL30726196 0.79 PARP1 (0.40) PARP1VCPCYP1A2CYP2D6CYP2C9
SCHEMBL248016 0.79 PARP1 (0.40) PARP1VCPCYP1A2CYP2D6CYP2C9
SCHEMBL20934619 0.78 S1PR1 (0.39) KDM4E
SCHEMBL30704786 0.78 S1PR1 (0.39) KDM4E
SCHEMBL8220975 0.78 UGT2B7 (0.44) PARP1CES2CES1ADRB1ADRA2A
SCHEMBL20764902 0.78 PARP1 (0.35) PARP1CES2CES1VCPADRB1
SCHEMBL19028362 0.78 UGT2B7 (0.44) PARP1CES2CES1ADRB1ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250221966-A1 RXFP1 AGONISTS BRISTOL MYERS SQUIBB CO (US) 2025-07-10 US disclosed
CN-118843613-A RXFP1 agonists 百时美施贵宝公司 2024-10-25 CN disclosed
EP-4422746-A1 RXFP1 AGONISTS Bristol-Myers Squibb Company (US) 2024-09-04 EP disclosed
WO-2023076626-A1 RXFP1 AGONISTS BRISTOL-MYERS SQUIBB COMPANY (US) 2023-05-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221966-A1 RXFP1 AGONISTS RXFP1, RXFP2, RXFP3 PARP1 4751/4885CES2 3755/4885CES1 444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.